Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
Nautilus Biotechnology (NASDAQ: NAUT) has joined the Human Proteome Organization's Industrial Advisory Board (IAB), enhancing its role in the proteomics field.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT) has joined the Human Proteome Organization's Industrial Advisory Board (IAB), enhancing its role in the proteomics field. Announced on September 1, 2022, this collaboration allows Nautilus to provide expertise in technology and product innovation while engaging with industry leaders. Co-founder Parag Mallick expressed excitement about participating as a Gold Sponsor at the upcoming 2022 HUPO World Congress.
Nautilus aims to democratize access to the proteome, driving advancements in human health and medicine.
Positive
- Joining the HUPO IAB positions Nautilus as an influential voice in proteomics.
- Participation as a Gold Sponsor at the premier HUPO World Congress enhances visibility.
Negative
- None.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -1.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Representatives of company developing platform for comprehensively quantifying the proteome to provide HUPO leadership with input on technology and product innovation
SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB).
Since its creation in 2006, the HUPO IAB has comprised industry leaders in the field of proteomics. As a member company, Nautilus will serve as an influential voice providing valuable input on technology and product innovation to the HUPO Council and its Executive Committee, as well as on industry trends relevant to HUPO and its pharmaceutical and biotechnology members and partners. The globally active committee supports academic and industrial leaders driving the development of innovative proteomics technologies and standards.
“We are delighted to join the HUPO Industrial Advisory Board and to more broadly contribute to the proteomics community,” said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. “Nautilus is looking forward to participating as a Gold Sponsor of the 2022 HUPO World Congress, the premier international conference for proteomics.”
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.